Basket | Login | Register

 
 
 
 

Biogen has submitted the Marketing Authorization Application to EMA for aducanumab

Wednesday 21 October 2020

On 21 October, the biotechnology company Biogen reported its third quarter 2020 financial results. In the third quarter, Biogen continued to execute on its strategy and had a total revenue of USD 3,376 million. In this press release, it was also disclosed that Biogen submitted the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the review of aducanumab as a treatment for Alzheimer’s disease (AD). The application is subject to validation of whether the EMA accepts the application for review.

https://investors.biogen.com/static-files/9d0b52a8-22b5-4742-af9d-8138469ac89f

Options